Fig. 2: FOXK2 activity is stimulated by SUMOylation.
From: SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells
a MCF-7 cells were transfected with the empty vector (pCMV5), wild-type FOXK2 and SUMO-mutant FOXK2 vector (K527/633 R), seeded in 96-well plates and treated with increasing concentrations of paclitaxel. After 24, 48 and 72 h of incubation with the drugs, cell viability was assessed by SRB assay. Bars represent average ± s.d. from three independent experiments. Statistical significant differences between cells transfected with the wild-type and K527/633 R were determined by Student’s t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, significant). b MCF-7 cells were transfected with the empty vector (pCMV5), wild-type FOXK2 and SUMO-mutant FOXK2 vector (K527/633 R), seeded in 6-well plates and treated with increasing concentrations of paclitaxel. After 48 h of incubation with the drugs, cells were cultured in fresh media, grown for around 14 days and stained with crystal violet. The graphs are representative of three experiments. Statistical significant differences between cells transfected with the wild-type and K527/633 R were determined by Student’s t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, significant)
